Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease - Wikidata - wikimedia - TriplyDB

Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease

Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease

http://www.wikidata.org/entity/Q24647189

about

Long-term artificial sweetener acesulfame potassium treatment alters neurometabolic functions in C57BL/6J mice Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders Hippocampal Neurophysiologic Changes after Mild Traumatic Brain Injury and Potential Neuromodulation Treatment Approaches Mouse models of polyglutamine diseases: review and data table. Part I Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.GIT2 acts as a potential keystone protein in functional hypothalamic networks associated with age-related phenotypic changes in rats Altered hypothalamic protein expression in a rat model of Huntington's disease Amitriptyline improves motor function via enhanced neurotrophin signaling and mitochondrial functions in the murine N171-82Q Huntington disease model.BDNF mediates adaptive brain and body responses to energetic challenges Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis Energy intake and exercise as determinants of brain health and vulnerability to injury and disease A synopsis on the role of tyrosine hydroxylase in Parkinson's disease Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies Insulin Resistance as a Link between Amyloid-Beta and Tau Pathologies in Alzheimer's Disease.Adverse stress, hippocampal networks, and Alzheimer's disease.Metabolic and hormonal signatures in pre-manifest and manifest Huntington's disease patients.Vasoactive intestinal peptide-null mice demonstrate enhanced sweet taste preference, dysglycemia, and reduced taste bud leptin receptor expression.Insulin and glucagon regulate pancreatic α-cell proliferation The impact of dietary energy intake on cognitive aging.Toll-like receptor 3 inhibits memory retention and constrains adult hippocampal neurogenesis.Adenosine, ketogenic diet and epilepsy: the emerging therapeutic relationship between metabolism and brain activity Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.The mammalian tachykinin ligand-receptor system: an emerging target for central neurological disorders Intracerebroventricular injection of encapsulated human mesenchymal cells producing glucagon-like peptide 1 prolongs survival in a mouse model of ALS.Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits.Diminished mTOR signaling: a common mode of action for endocrine longevity factors.Aberrant subcellular neuronal calcium regulation in aging and Alzheimer's disease Bidirectional metabolic regulation of neurocognitive function.Altered lipid and salt taste responsivity in ghrelin and GOAT null mice.Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats.ER stress-induced eIF2-alpha phosphorylation underlies sensitivity of striatal neurons to pathogenic huntingtin GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice Neuroprotective effects of exendin-4 in rat model of spinal cord injury via inhibiting mitochondrial apoptotic pathway.Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders Delivery of two-step transcription amplification exendin-4 plasmid system with arginine-grafted bioreducible polymer in type 2 diabetes animal model.

P2860

Q21132667-FC37283D-A6DF-4EDC-AD7D-04EF6A8CF9C8 Q24562763-AB04A1D5-9476-49AD-A530-3B76118A28C9 Q26768199-4EFE516F-668F-4863-A6D3-17A776EA06AB Q26853025-082B471E-93EE-4A01-B8FB-9FB340A1BD71 Q26999386-E8DB5B05-EE15-47E0-B94E-F9D5B1A85A8C Q27005950-90437B7F-D21E-4126-B82D-1F76F01233DD Q27302985-ECBE9F44-FA53-4CB3-8864-3DEC5BDD6708 Q27314833-50623E15-A9C7-4C3F-9D8D-3BE767E368D8 Q27314860-6648F3D7-0548-4367-9756-82635B053588 Q27693260-E8CC5C6E-2C2C-4AAA-BABF-54BFAD241046 Q28481242-61F89DCF-4AB2-4D58-AA91-678DB9B867FB Q28710367-589B3FD7-8604-4662-BA94-A0EA896CCD6B Q28830946-3742F6D5-1091-43D9-8AD0-50C539988E41 Q30531048-17888C3C-6353-43FC-A9BF-0860A26D137D Q33517121-AEAFFAC4-1C6A-4EC3-89BD-8D5AA9E04CE9 Q33624771-F8CCD68B-DDD9-41BF-8548-E68ABA51732A Q33628048-BECC2BC8-D0B6-4CAC-9C86-C4E819BEE38A Q33708011-DAAEF125-43DC-40FE-8DCB-04E7E97D241C Q33789754-C984E4FF-BAC7-4DD7-BF4C-FC86A9D37068 Q33803426-34D51D55-BF45-4894-8EDA-85072B922F70 Q33808713-4045076F-0D63-474E-A95A-0D92F26D85B8 Q33868403-B1AADFE7-FBF8-4070-BB4C-DF35011FFE0E Q34100406-01D24481-6794-43BE-8CAF-6C06697D7A92 Q34101256-160A5FA5-ED10-4116-8931-CD86CC9EB023 Q34128861-D2498158-7424-4B1B-87B1-C383F2354ECA Q34167980-CF9359C9-41C3-4F49-B84C-90CE1D50A9A2 Q34259043-983EEC1E-A697-46BC-A2B3-DE86F1B590F4 Q34321059-4D387920-E82C-40B7-8A74-5B7C26157874 Q34362412-EF0454D6-F86C-4D82-A93E-9A056E980752 Q34379379-355F5516-467B-4C15-BAC6-72419C61A7F1 Q34462362-B7FE58FC-0D81-419D-A8EE-2674B6101E8F Q34547754-CD90A447-72C7-40C2-AFD9-FAF27591EEA5 Q34884241-EBDA568D-7A5B-4588-BC08-A735206C1438 Q35017008-A5EF4542-B2A4-474C-90F0-1C0904B80859 Q35061438-9EBCEFD5-4598-49DF-A896-2C95FCE31637 Q35110977-E193FEA4-B012-4F27-8567-630ABBFF3617 Q35226164-B55FA9A7-099D-45EB-95F6-E352E553D1BB Q35853973-0BD0BB05-D76F-44FA-8D82-908F1F5FA717 Q36166654-4BBC4D43-4800-4A5F-B706-A2FD29831E87 Q36186706-ABEF8CEB-A45C-4D09-A8E4-84E3DD17DC0A

P2860

Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease

http://www.wikidata.org/entity/Q24647189

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Exendin-4 improves glycemic co ...... model of Huntington's disease

@ast

Exendin-4 improves glycemic co ...... model of Huntington's disease

@en

Exendin-4 improves glycemic co ...... model of Huntington's disease

@nl

type

label

Exendin-4 improves glycemic co ...... model of Huntington's disease

@ast

Exendin-4 improves glycemic co ...... model of Huntington's disease

@en

Exendin-4 improves glycemic co ...... model of Huntington's disease

@nl

prefLabel

Exendin-4 improves glycemic co ...... model of Huntington's disease

@ast

Exendin-4 improves glycemic co ...... model of Huntington's disease

@en

Exendin-4 improves glycemic co ...... model of Huntington's disease

@nl

P1433

Q24647189-A44A7B7C-1E04-47B5-A180-F1C2136E51C4

P1476

Q24647189-3E8ABFDE-301F-4B75-8B93-112646127C94

P2093

Q24647189-28C54F8D-8D03-46EB-BC8C-FE9EC19559CA

Q24647189-2FE79B4B-47B9-44C1-8F3F-16E5BAC44492

Q24647189-4F7E0F94-A3F1-441E-AA26-06AAF6B577EC

Q24647189-54002C0D-4366-4F04-955E-F206A4508D47

Q24647189-5B15F9A0-F25E-42F4-B54B-79BF998B21E2

Q24647189-8CF3FD9B-F2E1-4E3E-8C46-F549CF89707C

Q24647189-8D54C308-EBB9-4AAC-8A4C-202F7231F882

Q24647189-9BF6F609-BC8E-4546-88E4-48F712EA9D39

Q24647189-AAE122D3-6749-4E1D-8D44-D5D250AD5B31

Q24647189-AE08C47A-3537-492C-BE41-6359FACBF162

P2860

Q24647189-031494A1-1F32-41E8-A4F3-1C52677DEDF2

Q24647189-0316CC20-DEAA-472A-A39B-852E19DE246A

Q24647189-0719A34B-12E1-4004-BEBD-E5E7BB9A0776

Q24647189-0A7072FF-9FC5-4FC5-891F-FF4D6A3B366E

Q24647189-0C607E60-8436-48CA-920C-2BEEECB2559D

Q24647189-0F6FEBB7-041B-426E-9352-9438DC56BE10

Q24647189-1239788B-1D96-4221-94E9-B35D6D3B138A

Q24647189-17A25475-2313-4121-8C40-80098963BE15

Q24647189-1C30FA04-8A4A-4D62-882C-CA4737A1A4C3

Q24647189-1ECBB798-BB2B-49A6-848C-E86F7DED745E

P304

Q24647189-9DDCD4A1-7C3C-4D14-957B-3A92B359BE81

P31

Q24647189-FCACAB22-8990-4467-A0F5-CB63267917FD

P356

Q24647189-F81943D6-A72C-48DE-A8CA-42B7366652FC

P407

Q24647189-51524F44-D951-424E-8091-C6D39D92D81C

P433

Q24647189-57D56F11-C444-410F-9D1C-7D6CD45F72FE

P478

Q24647189-0BD0CD2C-5B77-4E10-B529-07D390550959

P50

Q24647189-7B0A53BA-0C5B-4917-98F8-CF4446E569D5

Q24647189-B8E6C00B-69B8-4571-932F-8ED49961197A

Q24647189-D22A8E5F-C4EF-4576-9C09-7541ADBDADF7

Q24647189-E8A49F66-5D46-4A3D-AA0E-182B5B11A6C2

P577

Q24647189-9EC5368C-9841-4067-BA24-87DB16D6A38C

P5875

Q24647189-026A5E7A-2633-4790-83AB-4EB212423B76

P698

Q24647189-07BAAA9A-EE0B-4013-A8CE-B217BDFB86FF

P921

Q24647189-5008B385-2078-433D-A3DB-2DAC12131590

Q24647189-5331f974-828c-47fb-9b78-578761642a9d

Q24647189-C9D2C18F-5E0B-4974-B2D5-CA9575D6372A

P932

Q24647189-7FF9C0F4-76C5-43E0-8708-94A0474A23DF

P356

P1433

P1476

Exendin-4 improves glycemic co ...... model of Huntington's disease

@en

P2093

Brittany P Frank

http://www.w3.org/2001/XMLSchema#string

Bronwen Martin

http://www.w3.org/2001/XMLSchema#string

Erin Golden

http://www.w3.org/2001/XMLSchema#string

Jie Zhou

http://www.w3.org/2001/XMLSchema#string

Kirupa Sathasivam

http://www.w3.org/2001/XMLSchema#string

Nigel H Greig

http://www.w3.org/2001/XMLSchema#string

Olga D Carlson

http://www.w3.org/2001/XMLSchema#string

Paul Pistell

http://www.w3.org/2001/XMLSchema#string

Sam Thomas

http://www.w3.org/2001/XMLSchema#string

Stuart Maudsley

http://www.w3.org/2001/XMLSchema#string

P2860

The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor

Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

Mechanisms of action of glucagon-like peptide 1 in the pancreas

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

Huntingtin aggregation and toxicity in Huntington's disease

The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease

Unbiased gene expression analysis implicates the huntingtin polyglutamine tract in extra-mitochondrial energy metabolism

Intracellular signalling. Key enzyme in leptin-induced anorexia

Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes

P304

318-28

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DB08-0799

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

Josephine M Egan

P577

2009-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23452002

http://www.w3.org/2001/XMLSchema#string

P698

18984744

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

2628604

http://www.w3.org/2001/XMLSchema#string